Influence of enhanced bioavailable curcumin on obesity-associated cardiovascular disease risk factors and arterial function: A double-blinded, randomized, controlled trial

Marilyn S. Campbell, An Ouyang, Krishnakumar I.M., Richard J. Charnigo, Philip M. Westgate, Bradley S. Fleenor

Research output: Contribution to journalArticlepeer-review

57 Scopus citations

Abstract

Objectives: This study aimed to determine whether an enhanced bioavailable curcumin formulation, CurQfen®, would improve circulating cardiovascular disease–related blood biomarkers and arterial function in young (age 18–35 y), obese (body mass index ≥ 30.0 kg/m 2 ) men. Methods: This double-blinded, placebo-controlled trial evaluated 22 men. The participants were matched based on body mass index and randomized to the intervention (curcumin formulated with fenugreek soluble fiber, for enhanced absorption) or control (fenugreek soluble fiber) group for 12 wk at 500mg/d without dietary modification or exercise. Blood samples and endothelial function measures were acquired at 0 and 12 wk, and blood samples were analyzed for cardiovascular disease–related blood biomarkers. Furthermore, central (aortic) blood pressure and augmentation index were monitored at 0, 4, 8, and 12 wk. Results: After 12 wk of intervention, homocysteine levels were lower (curcumin before: 12.22 ± 2.29 µg/mL, after: 8.62 ± 1.02 µg/mL versus placebo before: 9.45 ± 0.84 µg/mL, after: 11.84 ± 1.63 µg/mL; P = 0.04) and high-density lipoprotein levels were higher (curcumin before: 40.77 ± 5.37 mg/dL, after: 54.56 ± 11.72 mg/dL versus placebo before: 61.20 ± 5.76 mg/dL, after: 48.82 ± 5.49 mg/dL; P = 0.04) in the curcumin group relative to the placebo group. However, there was no significant difference in changes between the circulating concentrations of glucose, insulin, leptin, adiponectin, or oxidative stress biomarkers in the curcumin group compared with the placebo group (P > 0.05). No changes were found with endothelial function, augmentation index, or central blood pressure in the curcumin group compared with the placebo group (P > 0.05). Conclusions: Our data provide evidence for an enhanced bioavailable curcumin to improve homocysteine and high-density lipoprotein concentrations, which may promote favorable cardiovascular health in young, obese men. Improvements in endothelial function or blood pressure were not observed with curcumin supplementation, thus further investigation is warranted.

Original languageEnglish
Pages (from-to)135-139
Number of pages5
JournalNutrition
Volume62
DOIs
StatePublished - Jun 2019

Bibliographical note

Publisher Copyright:
© 2019 Elsevier Inc.

Funding

Sources of support: This study was funded by Akay Flavours & Aromatics Pvt. Ltd. and the Arvle and Ellen Turner Thacker Research Fund and supported by the National Center for Advancing Translational Sciences, National Institutes of Health (grant number UL1 TR000117). Akay Flavours & Aromatics Pvt. Ltd. provided CurQfen® and the placebo supplements. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

FundersFunder number
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)UL1TR000117

    Keywords

    • Turmeric
    • adiposity
    • arteriosclerosis
    • intervention
    • vascular function
    • vasodilation

    ASJC Scopus subject areas

    • Endocrinology, Diabetes and Metabolism
    • Nutrition and Dietetics

    Fingerprint

    Dive into the research topics of 'Influence of enhanced bioavailable curcumin on obesity-associated cardiovascular disease risk factors and arterial function: A double-blinded, randomized, controlled trial'. Together they form a unique fingerprint.

    Cite this